186 related articles for article (PubMed ID: 20602088)
1. Contribution of limbic norepinephrine to cannabinoid-induced aversion.
Carvalho AF; Reyes AR; Sterling RC; Unterwald E; Van Bockstaele EJ
Psychopharmacology (Berl); 2010 Sep; 211(4):479-91. PubMed ID: 20602088
[TBL] [Abstract][Full Text] [Related]
2. Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion.
Carvalho AF; Van Bockstaele EJ
Neurosci Lett; 2011 Aug; 500(1):82-5. PubMed ID: 21693171
[TBL] [Abstract][Full Text] [Related]
3. Repeated cannabinoid administration increases indices of noradrenergic activity in rats.
Page ME; Oropeza VC; Sparks SE; Qian Y; Menko AS; Van Bockstaele EJ
Pharmacol Biochem Behav; 2007 Jan; 86(1):162-8. PubMed ID: 17275893
[TBL] [Abstract][Full Text] [Related]
4. Effect of Cannabinoid Receptor Agonists on Isolated Rat Atria.
Maggo S; Ashton JC
J Cardiovasc Pharmacol; 2018 Oct; 72(4):191-194. PubMed ID: 30080756
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
6. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
7. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring.
Shabani M; Hosseinmardi N; Haghani M; Shaibani V; Janahmadi M
Neuroscience; 2011 Jan; 172():139-52. PubMed ID: 20969930
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
Cui JH; Kim WM; Lee HG; Kim YO; Kim CM; Yoon MH
Neurosci Lett; 2011 Apr; 493(3):67-71. PubMed ID: 21195743
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid modulation of limbic forebrain noradrenergic circuitry.
Carvalho AF; Mackie K; Van Bockstaele EJ
Eur J Neurosci; 2010 Jan; 31(2):286-301. PubMed ID: 20074224
[TBL] [Abstract][Full Text] [Related]
11. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.
González C; Herradón E; Abalo R; Vera G; Pérez-Nievas BG; Leza JC; Martín MI; López-Miranda V
Diabetes Metab Res Rev; 2011 May; 27(4):331-40. PubMed ID: 21309057
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors.
Abalo R; Cabezos PA; Vera G; López-Miranda V; Herradón E; Martín-Fontelles MI
Neurogastroenterol Motil; 2011 May; 23(5):457-67, e177. PubMed ID: 21303434
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.
Fernández-López D; Martínez-Orgado J; Nuñez E; Romero J; Lorenzo P; Moro MA; Lizasoain I
Pediatr Res; 2006 Aug; 60(2):169-73. PubMed ID: 16864698
[TBL] [Abstract][Full Text] [Related]
15. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
Pozzi O; Misiano P; Clark GD; Visentin L
Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703
[TBL] [Abstract][Full Text] [Related]
16. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.
Luca T; Di Benedetto G; Scuderi MR; Palumbo M; Clementi S; Bernardini R; Cantarella G
Eur J Pharmacol; 2009 Aug; 616(1-3):16-21. PubMed ID: 19539619
[TBL] [Abstract][Full Text] [Related]
17. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid reward and aversion effects in the posterior ventral tegmental area are mediated through dissociable opiate receptor subtypes and separate amygdalar and accumbal dopamine receptor substrates.
Ahmad T; Laviolette SR
Psychopharmacology (Berl); 2017 Aug; 234(15):2325-2336. PubMed ID: 28669034
[TBL] [Abstract][Full Text] [Related]
19. Role of intra-accumbal cannabinoid CB1 receptors in the potentiation, acquisition and expression of morphine-induced conditioned place preference.
Karimi S; Azizi P; Shamsizadeh A; Haghparast A
Behav Brain Res; 2013 Jun; 247():125-31. PubMed ID: 23523958
[TBL] [Abstract][Full Text] [Related]
20. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.
Qamri Z; Preet A; Nasser MW; Bass CE; Leone G; Barsky SH; Ganju RK
Mol Cancer Ther; 2009 Nov; 8(11):3117-29. PubMed ID: 19887554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
